Located in Yizhuang’s Economic and Technological Development Area with a total area of about 60000 square meters, Eastern Biotech was founded in 2011 and became a leading biomedical R&D, production and sales company in China. The company's product categories include full human monoclonal antibody, humanized monoclonal antibody, bispecific antibody, antibody fusion protein, therapeutic vaccine, to name a few that target prevalent diseases such as malignant tumors, diabetes, autoimmune diseases (rheumatoid arthritis, psoriasis, ankylosing spondylitis, etc.), ophthalmic diseases, respiratory diseases, etc.

Here at Beijing Eastern Biotech, we have a biological drug research and development team with more than 100 people who laid out more than 20 research and development pipelines, obtained 7 approval documents for clinical trials of new drugs, and are conducting clinical trial research. We have undertaken a number of national "major new drug development", special projects of various ministries and commissions, the "863" plan and other key projects such as the 11th and 12th Five Year Plan. We always hold "quality and innovation" as the eternal pursuit and source of power for the company and remain attentive towards changes in the industry.
Our new large-scale industrial base in Yizhuang, Beijing, is under construction with a total investment of 1.5 billion yuan. The first phase covers an area of 30 mu (about 4.9 acres) where a 3 * 2000L mammal batch cultivation production line will be built. It will meet the advanced requirements of China and the United States GMP, and it is expected to be officially put into use in 2023.
Dongfang Baitai Biopharmaceutical Co., Ltd. (or Eastern Pharmaceutical), a subsidiary of Eastern Biotech, is one of the earliest companies to be engaged in antibody drug development in China. Its core product Tai Xin Sheng® (nimotuzumab) is the first humanized monoclonal antibody drug targeting nasopharyngeal cancer China, and it has a therapeutic effect on many other cancers such as: head and neck, pancreatic, breast, glioma, non-small cell lung, etc. It was added to the Chinese Pharmacopoeia in 2015 and the national medical insurance in 2017, significantly contributing to the field of biomedical antibodies in China!
Eastern Biotech has been successively awarded the titles of "Beijing Engineering Laboratory of Antibody Project" and "Beijing Engineering Research Center of Antibody Drugs". It is not only the "Beijing International Science and Technology Cooperation Base for New Antibody and Therapeutic Protein Drugs", but also the "National International Science and Technology Cooperation Base for Advanced Technologies of New Antibody and Therapeutic Protein Drugs". We have successively established a "Postdoctoral Scientific Research Workstation" a "Academician Expert Workstation", and we are certified by the national intellectual property management system and the International Organization for Standardization (ISO 9000).